Drug intelligence / Profile preview

trastuzumab rezetecan + camrelizumab

Development stage: Unknown
Lead developer: Jiangsu Hengrui Medicine
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Trastuzumab rezetecan + camrelizumab is an investigational combination therapy being evaluated for the treatment of HER2-positive muscle-invasive urothelial carcinoma (bladder cancer). The regimen consists of **trastuzumab rezetecan** (SHR-A1811), a HER2-directed antibody-drug conjugate (ADC), and **camrelizumab** (SHR-1210), an anti-PD-1 immune checkpoint inhibitor. Trastuzumab rezetecan utilizes a humanized anti-HER2 monoclonal antibody conjugated to a cytotoxic topoisomerase I inhibitor payload (rezetecan) via a cleavable linker. Camrelizumab is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, thereby restoring T-cell mediated anti-tumor immunity. This combination aims to synergize the direct cytotoxic effects of the ADC with the immune-potentiating activity of the checkpoint inhibitor to improve pathological complete response rates in the perioperative setting.

Other names: Ruikang Trastuzumab + CamrelizumabSHR-A1811 + camrelizumab

Targets

TOP1 (DNA Topoisomerase I)PDCD1 (Programmed cell death protein 1 receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on trastuzumab rezetecan + camrelizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on trastuzumab rezetecan + camrelizumab.

Explore the full profile